Shanghai Junshi Biosciences Co., Ltd.
1877.HK
Hong Kong Stock Exchange19.37
HKD
+0.79
- -
Shanghai Junshi Biosciences Co., Ltd.
1877.HK
(Hong Kong Stock Exchange)
Recent
price
19.37
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Shanghai Junshi Biosciences Co., Ltd. (1877.HK) engages in the discovery, development, and commercialization of innovative biopharmaceuticals targeting oncology, autoimmune diseases, chronic metabolic disorders, neurological conditions, and infectious diseases; its lead product toripalimab (TUOYI®/LOQTORZI®), a recombinant humanized anti-PD-1 monoclonal antibody, treats multiple malignancies including nasopharyngeal carcinoma, melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma, urothelial carcinoma, renal cell carcinoma, small cell lung cancer, and triple-negative breast cancer across frontline, perioperative, and relapsed settings; additional marketed therapies encompass ongericimab (JUNSHIDA®), a PCSK9 inhibitor for primary hypercholesterolemia and mixed dyslipidemia including statin-intolerant patients, adalimumab biosimilar (JUNMAIKANG®) for autoimmune conditions such as rheumatoid arthritis, and deuremidevir hydrobromide (MINDEWEI®/VV116), an oral nucleoside analog for COVID-19; the pipeline features antibody-drug conjugates like JS212 (EGFR×HER3 ADC) and JS107 (Claudin18.2 ADC), bispecific antibodies including JS207 (PD-1×VEGF) and JS213 (PD-1×IL-2), small molecules such as JS105 (PI3K-α), JS110 (XPO1), and JS125 (HDACs), and other modalities targeting BTLA (tifcemalimab), CTLA-4 (JS007), IL-17A (JS005), DKK1 (JS015), and nucleic acid drugs. Founded in 2012 and headquartered in Shanghai, China, the company operates innovation centers in Shanghai, Suzhou, and Maryland, U.S., with production bases in Suzhou Wujiang and Shanghai Lingang, serving domestic and international markets including approvals in the U.S., EU, UK, Canada, Australia, Singapore, India, UAE, Kuwait, Pakistan, Jordan, Hong Kong SAR, and Uzbekistan. Recent developments include a January 2025 commercialization partnership with LEO Pharma for toripalimab (LOQTORZI®) in Europe targeting cancer-associated thrombosis; a prior collaboration with Dr. Reddy's Laboratories for toripalimab in 21 countries; NMPA approvals in 2025 for toripalimab's sNDA as first-line treatment for melanoma and ongericimab's sNDAs for statin-intolerant hypercholesterolemia; Phase 3 success for JS005 (IL-17A) in moderate-to-severe plaque psoriasis; sNDA acceptance for toripalimab plus disitamab vedotin in HER2-expressing urothelial carcinoma; expanded global approvals for toripalimab in NPC and ESCC; and ongoing construction of the Suzhou Wujiang production base to enhance manufacturing capacity.
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis